MedTrace Logo

Neoadjuvant Anti-PD1 in HCC

NCT05471674 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-02-01

No results posted yet for this study

Summary

This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.

Conditions

Interventions

DRUG

Nivolumab

3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses

PROCEDURE

Hepatectomy

Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab

Sponsors & Collaborators

  • Dr Tan-to CHEUNG

    lead OTHER

Principal Investigators

  • Tan-to Cheung, MD · The University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05471674 on ClinicalTrials.gov